Please login to the form below

Not currently logged in
Email:
Password:

Merck MS drug denied FDA approval

Merck KGaA's marketing application for the investigational oral formulation of cladribine has not been approved by the FDA as a treatment for relapsing-remitting multiple sclerosis

The US Food and Drug Administration (FDA) has declined to approve Merck KGaA's marketing application for the company's proprietary investigational oral formulation of cladribine as a treatment for relapsing-remitting multiple sclerosis (MS).

In a complete response letter, the agency said the application could not be approved until the company provided "an improved understanding of safety risks and the overall benefit-risk profile either through additional analyses or by additional studies," according to Merck.

The FDA did acknowledge that substantial evidence of effectiveness was provided by Merck's CLARITY1 study, a two-year phase III placebo-controlled trial that evaluated cladribine tablets as a monotherapy in patients with relapsing-remitting MS.

Merck said it will request an end-of-review meeting with the FDA to determine whether new studies will be needed or whether data from completed and currently ongoing clinical studies will be sufficient to address the agency's concerns.

The company said it remains committed to completing the ongoing clinical trials, which are already fully enrolled. Merck expects to have top-line results from two of the ongoing studies by the end of 2011 and from a third in the first half of 2012.

The FDA originally granted cladribine tablets a priority review in July 2010 and had expected to make a decision on the product by November 28, 2010. However, at that time, the agency extended its review period by three months to February 28, 2011, in order to allow time for a full review of additional information provided by Merck at the agency's request.

The product was approved in Russia in July 2010 and in Australia in September 2010.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion regarding the marketing application for cladribine tablets as a treatment for relapsing-remitting MS.

3rd March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics